Topics
Glioblastoma | Treatment | Immunotherapy | CAR-T-Cells
Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > CAR-T-Cells
Bagley SJ, Binder ZA, Lamrani L,
Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA,
Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W,
Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan
S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K,
Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon
JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM.
Repeated
peripheral infusions of anti-EGFRvIII CAR T cells in combination
with pembrolizumab show no efficacy in glioblastoma: a phase 1
trial.
Nat
Cancer. 2024 Jan
12. doi:
10.1038/s43018-023-00709-6. PMID:
38216766. Interventional study˰ ˍ
Zhu N, Chen S, Jin Y, Wang M, Fang L, Xue L, Hua D, Zhang Z, Jia
M, Hao M, Zhang C.
Enhancing
Glioblastoma Immunotherapy with Integrated Chimeric Antigen
Receptor T Cells through the Re-Education of Tumor-Associated
Microglia and Macrophages.
ACS
Nano. 2024 Apr 16. doi:
10.1021/acsnano.4c00050. PMID:
38626338. Laboratory investigation˰
ˍ
Montoya
M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H.
A
Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and
Future Perspectives.
Cells.
2024 Apr 23;13(9):726. doi:
10.3390/cells13090726. PMID:
38727262. Review. ˍ
*Akhavan D, Subham S, Jeppson JD, Aguilar B, Wong RA, Hibbard JC,
Hui S, Wong JYC, Forman SJ, Alizadeh D, Brown CE.
Evaluation
of the Immunomodulatory Effects of Radiation for Chimeric Antigen
Receptor T Cell Therapy in Glioblastoma Multiforme.
Cells.
2024 Jun 21;13(13):1075. doi:
10.3390/cells13131075. PMID:
38994929.
Laboratory investigation. ˍ
Agosti E, Garaba A, Antonietti S, Ius T, Fontanella MM, Zeppieri
M, Panciani PP.
CAR-T Cells Therapy in
Glioblastoma: A Systematic Review on Molecular Targets and
Treatment Strategies.
Int
J Mol Sci. 2024 Jun 29;25(13):7174. doi:
10.3390/ijms25137174. PMID:
39000281. Review. ˍ
Lu J, Huo W, Ma Y, Wang X, Yu J.
Suppressive
immune microenvironment and CART therapy for glioblastoma: Future
prospects and challenges.
Cancer
Lett. 2024 Aug 12;600:217185. doi:
10.1016/j.canlet.2024.217185. PMID:
39142498. Review. ˍ
Sterner RC, Sterner RM.
EGFRVIII and
EGFR targeted chimeric antigen receptor T cell therapy in
glioblastoma.
Front
Oncol. 2024 Sep 19;14:1434495. doi:
10.3389/fonc.2024.1434495. PMID:
39364321. Review. ˍ
Luo Y, Gadd ME, Qie Y, Otamendi-Lopez A, Sanchez-Garavito JE,
Brooks MM, Ulloa Navas MJ, Hundal T, Li S, Jones VK, Lou Y, Patel
T, Dronca R, Kharfan-Dabaja MA, Dong H, Quinones-Hinojosa A, Qin
H.
Solid cancer-directed CAR T cell
therapy that attacks both tumor and immunosuppressive cells via
targeting PD-L1.
Mol
Ther Oncol. 2024 Oct 5;32(4):200891. doi:
10.1016/j.omton.2024.200891. PMID:
39498357. Laboratory investigation. ˍ
*Sandhanam K, Tamilanban T, Bhattacharjee B, Manasa K.
Exploring
miRNA therapies and gut microbiome-enhanced CAR-T cells: advancing
frontiers in glioblastoma stem cell targeting.
Naunyn
Schmiedebergs Arch Pharmacol. 2024 Oct 9. doi:
10.1007/s00210-024-03479-9. PMID:
39382681. Review˰ ˍ
Sabahi M, Fathi Jouzdani A, Sadeghian Z, Dabbagh Ohadi MA, Sultan
H, Salehipour A, Maniakhina L, Rezaei N, Adada B, Mansouri A,
Borghei-Razavi H.
CAR-engineered
NK cells versus CAR T cells in treatment of glioblastoma;
strength
and flaws.
J
Neurooncol. 2024 Nov 13. doi:
10.1007/s11060-024-04876-z. PMID:
39538038. Review˰ ˍ